生命科学资讯
生物技术与制药领域的最新动态
Generate caps a strong month for biotech IPOs with $400M offering
Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics - The Korea Herald
随着CAR-T细胞疗法在实体瘤领域取得进展，监管繁文缛节阻碍发展步伐。
As CAR-T cell therapy gains ground on solid tumors, regulatory red tape hinders progress
'如同对牛弹琴'：参议院听证会直指FDA罕见病审批流程问题
'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process
安捷伦科技(A)利润率下滑挑战盈利改善的乐观预期 - simplywall.st
Agilent Technologies (A) Margin Slippage Challenges Bullish Earnings Improvement Narrative - simplywall.st
安捷伦科技(A)利润率下滑挑战盈利改善乐观预期 - simplywall.st
Agilent Technologies (A) Margin Slippage Challenges Bullish Earnings Improvement Narrative - simplywall.st
新一代正在塑造罕见病的未来 - Illumina
The next generation is shaping the future of rare diseases - Illumina
分析师观点汇总：九位专家眼中的安捷伦科技——来自Benzinga的报道
The Analyst Verdict: Agilent Technologies In The Eyes Of 9 Experts - Benzinga
司法部敦促最高法院撤销对希克玛“瘦身标签”案的复审。
DOJ urges Supreme Court to undo revival of Hikma ‘skinny label’ case
萨雷普塔CEO道格·英格拉姆的意志力遭遇挑战，计划离职。
Doug Ingram’s force of will meets its match as Sarepta CEO plans to depart
FDA借助外部力量调查内部普拉萨德投诉。
FDA probes internal Prasad complaints with outside help
勃林格殷格翰肺癌药物获加速批准用于一线治疗。
Boehringer wins accelerated approval for first-line use of lung cancer drug
Sarepta首席执行官道格·英格拉姆在杜氏肌营养不良症领域取得突破与争议十年后宣布退休。
Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies
分析师看好MDMA药物潜力，AtaiBeckley焦虑试验报告改善显著。
Analysts see potential in MDMA drug after AtaiBeckley reports improvements in anxiety trial
安捷伦科技(A)获瑞银分析师调整目标价 | A股新闻 - GuruFocus
Agilent Technologies (A) Sees Analyst Price Target Adjustment by UBS | A Stock News - GuruFocus
瑞银集团将安捷伦科技（NYSE:A）目标股价下调至165.00美元 - MarketBeat
UBS Group Lowers Agilent Technologies (NYSE:A) Price Target to $165.00 - MarketBeat
参议院听证会引发对罕见病新药FDA相关问题的担忧
Senate hearing raises FDA-related concerns for new rare disease drugs
尼安德特人与现代人类交配中发现的惊人伴侣偏好
Surprising partner preference found in matings between Neanderthals and modern humans
安捷伦科技第一季度盈利未达预期，股价下跌 - Investing.com
Agilent Technologies shares fall after Q1 earnings miss - Investing.com